Colistin Resistance Mechanism and Management Strategies of Colistin-Resistant Acinetobacter baumannii Infections
Open Access
Abstract
The emergence of antibiotic-resistant Acinetobacter baumannii (A. baumannii) is a pressing threat in clinical settings. Colistin is currently a widely used treatment for multidrug-resistant A. baumannii, serving as the last line of defense. However, reports of colistin-resistant strains of A. baumannii have emerged, underscoring the urgent need to develop alternative medications to combat these serious pathogens. To resist colistin, A. baumannii has developed several mechanisms. These include the loss of outer membrane lipopolysaccharides (LPSs) due to mutation of LPS biosynthetic genes, modification of lipid A (a constituent of LPSs) structure through the addition of phosphoethanolamine (PEtN) moieties to the lipid A component by overexpression of chromosomal pmrCAB operon genes and eptA gene, or acquisition of plasmid-encoded mcr genes through horizontal gene transfer. Other resistance mechanisms involve alterations of outer membrane permeability through porins, the expulsion of colistin by efflux pumps, and heteroresistance. In response to the rising threat of colistin-resistant A. baumannii, researchers have developed various treatment strategies, including antibiotic combination therapy, adjuvants to potentiate antibiotic activity, repurposing existing drugs, antimicrobial peptides, nanotechnology, photodynamic therapy, CRISPR/Cas, and phage therapy. While many of these strategies have shown promise in vitro and in vivo, further clinical trials are necessary to ensure their efficacy and widen their clinical applications. Ongoing research is essential for identifying the most effective therapeutic strategies to manage colistin-resistant A. baumannii. This review explores the genetic mechanisms underlying colistin resistance and assesses potential treatment options for this challenging pathogen.Keywords
All Related Versions
Funding Information
- National Research Foundation of Korea (NRF) funded by the Ministry of Education (2022R1F1A1071415, NRF-RS-2023-00275307, 2019R1A6C1010033)
- Korea Basic Science Institute (National Research Facilities and Equipment Center) grant funded by the Ministry of Education (2022R1F1A1071415, NRF-RS-2023-00275307, 2019R1A6C1010033)
This publication has 209 references indexed in Scilit:
- Artificial intelligence for drug repurposing against infectious diseasesArtificial Intelligence Chemistry, 2024
- Rescuing humanity by antimicrobial peptides against colistin-resistant bacteriaApplied Microbiology and Biotechnology, 2022
- Gold nanoparticle-DNA aptamer-assisted delivery of antimicrobial peptide effectively inhibits Acinetobacter baumannii infection in miceJournal of Microbiology, 2021
- Can Drug Repurposing be Effective Against Carbapenem-Resistant Acinetobacter baumannii?Current Microbiology, 2021
- In Vitro Activities of Tigecycline in Combination with Amikacin or Colistin Against Carbapenem-Resistant Acinetobacter baumanniiApplied Biochemistry and Biotechnology, 2021
- Mobilized colistin resistance (mcr) genes from 1 to 10: a comprehensive reviewMolecular Biology Reports, 2021
- Syzygium aromaticum (clove) and Thymus zygis (thyme) essential oils increase susceptibility to colistin in the nosocomial pathogens Acinetobacter baumannii and Klebsiella pneumoniaeBiomedicine & Pharmacotherapy, 2020
- Colistin heteroresistance in carbapenem-resistant Acinetobacter baumannii clinical isolates from a Thai university hospitalWorld Journal of Microbiology and Biotechnology, 2020
- Contribution of EmrAB efflux pumps to colistin resistance in Acinetobacter baumanniiJournal of Microbiology, 2017
- The outer membrane porin OmpW of Acinetobacter baumannii is involved in iron uptake and colistin bindingFEBS Letters, 2015